8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 6, 2008

Date of Report (Date of earliest event reported)

PRO-PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

NEVADA	000-32877	04-3562325
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

7 WELLS AVENUE

NEWTON, MASSACHUSETTS

02459

(Address of Principal Executive Offices) (Zip Code)

(617) 559-0033

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Theodore Zucconi, Ph.D., President of Pro-Pharmaceuticals, Inc. (“Company”), today is presenting a corporate update as reflected in the slides attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) at a Russ Trading Investor Meeting in Tempe, AZ, and is scheduled to present a corporate update at the Red Chip Small Cap Investor Conference tomorrow in Scottsdale, AZ.

The information in this Report, including the slides attached hereto as Exhibit 99.1, is being furnished pursuant to this Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Report.

By filing this Report and furnishing this information, the Company makes no admission as to the materiality of any information in this Report. The information contained in the slides is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The Company cautions you that information included in the slides attached hereto as Exhibit 99.1 that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause the Company’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such forward-looking statements are made based on management’s current expectations and beliefs and should not be regarded as a statement or representation by the Company that any of its plans, including its anticipated milestones, will be achieved on time or at all. The Company’s public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company assumes no obligation to revise or update any forward-looking statement, including any information included in the slides attached hereto as Exhibit 99.1, to reflect events or circumstances arising after the date on which it was made. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

Item 8.01. Other Events.

On January 30, 2008, Custom Equity Research, Incorporated (d/b/a Summer Street Research Partners) (“Summer Street”) filed a lawsuit against the Company in the Superior Court of the Commonwealth of Massachusetts, alleging claims for breach of contract, declaratory judgment and unjust enrichment arising out of an engagement letter under which Summer Street agreed to provide institutional investment placement services to the Company. Summer Street claims it is entitled to a placement fee for each placement made during the term of the agreement and for each issuance of securities made or agreed to be made by the Company from October 17, 2007 through November 16, 2008. The Company believes the lawsuit is without merit and intends to contest it vigorously.

Item 9.01. Financial Statements and Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Index to Exhibits filed with this report.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRO-PHARMACEUTICALS, INC.
By:	/s/ Anthony Squeglia
	Anthony Squeglia Chief Financial Officer

Date: February 6, 2008

Exhibit Index

Number Exhibit	Exhibit
99.1	Russ Trading Investor Meeting - Presentation Slides - dated February 6, 2008.

EX-99.1

P  R  O      -

P  H  A  R  M  A  C  E  U  T  I  C  A  L  S ,    I  N  C .

Amex: P R W

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E®

Exhibit 99.1

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Forward Looking Statements

Any

statements

in

this

presentation

about

future

expectations,

plans

and

prospects

for

the

Company,

including

statements

containing

the

words

"believes,"

"anticipates,"

"plans,"

"expects

and

similar

expressions,

constitute

forward

looking

statements,

which

are

subject

to

the

safe

harbor

for

such

statements

in

the

Private

Securities

Litigation

Reform

Act

of

1995.

Future

events

could

cause

actual

results

to

differ

materially

from

those

indicated

by

such

statements.

Reference

is

made

to

the

factors

discussed

in

the

"Plan

of

Operations"

and

"Risk

Factors"

sections

of

the

Company's

most

recent

quarterly

or

annual

report

filed

with

the

Securities

and

Exchange

Commission.

The

forward-

looking

statements

herein

represent

the

Company's

views

as

of

the

date

of

this

presentation

and

should

not

be

relied

upon

to

represent

the

Company's

views

as

of

a

subsequent

date.

While

the

Company

anticipates

that

subsequent

events

may

cause

the

Company's

views

to

change,

the

Company

disclaims

any

obligation

to

update

such

forward-

looking statements.

2

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Mission

Develop proprietary carbohydrate

compounds with the potential to

significantly improve treatments for 

cancer, liver, inflammatory and microbial

diseases. This improvement is based on

identifying and exploiting the unique

biological specificity carbohydrates have

for disease receptors.

3

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Summary

•

Unique Technology

–

Multiple drug platforms

•

Positive pre-clinical and clinical trial

results

•

Regulatory Strategy

•

Business Opportunities

–

Multi-billion dollar markets

4

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Technology

5

•

Oncology

•

Fibrosis

•

Other opportunities

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Overview -

Technology

•

Unique Technology

–

Drug design using carbohydrates

–

Five

patents

issued

and

eleven

pending

–

Highly specific recognition mechanisms

6

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Strong Intellectual Property Position 

Carbohydrate Polymers

•

Composition of matter and field of use

patents (5)

–

U.S. Pat 6,642,205

(11/04/03) –

Methods and

Compositions for Reducing side effects in

Chemotherapeutic Treatments

–

U.S. Pat 6,645,946

(11/11/03) & U.S. Pat 6,982,255

(01/03/06) & U.S. Pat 6,914,055

(07/05/06) –

Delivery of

a Therapeutic Agent in a Formulation for Reduced

Toxicity

–

U.S. Pat 7,012,068

(03/14/06) –

Co-administration of a

Polysaccharide with a Chemotherapeutic agent for the

Treatment of Cancer

7

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Composition of Matter and Methods of Delivery

Key Claims

•

Methods and compositions for reducing toxicity of an

existing chemotherapeutic drug by co-administering a

polysaccharide

•

UNIVERSAL CARBOHYDRATE LINKER

TECHNOLOGY (UCLT™) enhances the delivery of

chemotherapy drugs to tumor cells

•

Covalently binds one carbohydrate compound to a

chemotherapy drug

•

Utilizes carbohydrate specific receptors found on

cancer cells to target delivery

8

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Strong Intellectual Property Position 

11 new patent applications filed

•

2 -

enhanced treatment of cancer

including reduced side effects

•

3 -

delivery of anti-cancer drugs

•

1 -

reducing side effects of

chemotherapeutic treatments

•

1 -

formulation for anti-fibrotic therapies

•

2 –

carbohydrate derived statins

•

1 -

composition of anti-microbial agent

•

1-

compositions and methods to inhibit

restenosis

9

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

LEAD COMPOUND

10

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Targeting Lectins

•

Lectins are proteins that tightly bind certain

carbohydrates

•

Galectins are a type of lectin that specifically bind

galactose molecules

•

Galectin receptors are predominately on cancer

cells

•

Galectins have been shown to affect cell

development, differentiation, apoptosis and tumor

metastasis

11

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

•

Proprietary polysaccharide that targets

Galectin receptors on cancer cells

•

Increases efficacy and decreases toxicity of

chemotherapeutic agents

•

Currently in Phase ll trials

DAVANAT

®

12

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

•

DAVANAT

®

selectively binds to lectin

receptors on cancer cells

•

Once bound, the polymer releases its

payload into the cancer cell

Oncology Platform: CARBOSOME™

13

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Second

Platform:

Universal Carbohydrate Linker Technology

•

New chemical entity that contains a carbohydrate backbone

14

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

CLINICAL TRIAL RESULTS

15

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Pre-Clinical Results

DAVANAT®

mixed with Avastin®

and with 5-FU

showed best results –

SLOWEST TUMOR GROWTH

Tumor Weight Gain in Mice Implanted with COLO 205, Human

Colon Tumor, Treated with DAVANAT® in Combination with 5-FU

& Bevacizumab (Avastin®)

0.0

10.0

20.0

30.0

40.0

50.0

60.0

70.0

80.0

90.0

100.0

Southern Research Institute (Dose: I.V., Q4D x 4, of 5-FU  50 mg/kg; DAVANAT®:  120 mg/kg;

AVASTIN:  20-80 mg/kg)

No Treatment

AV

FU / AV

FU-DAV / AV

FU-DAV / AV-DAV

16

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Pre-Clinical Results

DAVANAT®

mixed with Avastin and with 5-FU showed

best results –

Mice Show Healthy Weight Gain

Total Weight Gain of Mice Implanted with COLO 205, Human Colon

Tumor, Treated with DAVANAT® in Combination with 5-FU &

Bevacizumab (Avastin®)

-8.0

-4.0

0.0

4.0

8.0

Southern Research Institute (Dose: I.V., Q4D x 4, of 5-FU  50 mg/kg; DAVANAT®:  120 mg/kg; AVASTIN:

20-80 mg/kg)

No Treatment

AV

FU / AV

FU-DAV / AV

FU-DAV / AV-DAV

17

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Pre-Clinical Results

DAVANAT®

mixed with Avastin and with 5-FU showed best   

results –

Clinical Benefit Index = Lowest Toxicity and Best Efficacy

18

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

0

10

20

30

40

0

10

20

30

40

AUC

Hematocrit

Hemoglobin

Red blood cells

White blood cells

Platelets

Clinical  Trial Results

DAVANAT®

mixed with 5-FU eliminated the

expected drop in blood levels from chemotherapy

19

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Clinical Trial Summary

Results

•

48

patients

dosed

with

DAVANAT

®

/5-FU

in

Phase

l/ll,

Line

three

and

four

clinical

trials

•

Stabilized

43%

of

end

stage

patients

with

measurable

disease:       

2-13 months

•

Maximum

Tolerated

Dose/Dose

Limiting

Toxicity

not

reached

•

DAVANAT

®

allowed

increased

5-FU

exposure

with

no

toxicity

increase

Ongoing

•

Dosing

biliary

and

colorectal

cancer

patients

in

Phase

ll,

line

one

trials:

–

Colorectal

(8

patients

dosed)

–

3

PR;

4

stabilized

up

to

10

months

–

43%

Objective

Response

(more

than

30%

shrinkage)

20

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Beyond Oncology

-New Platforms-

•

Use Proprietary IP to Design New Drugs

•

Fibrosis –

Multiple Indications

•

Anti-Microbial

•

Synthetic Statins (Cholesterol)

21

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

FIBROSIS

22

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Fibrosis -

Background

•

Worldwide, 170 million people are infected with chronic hepatitis C

•

10-40% of patients respond to current therapies (notably, removal 

of cause)

–

There are no effective therapeutic options

–

1.4 million deaths per year attributed to chronic liver disease

–

In the U.S., liver disease is a top 10 disease-related cause of

death

•

Liver fibrosis is an outcome of persistent hepatic inflammation

•

World wide market in excess of $4 billion

•

Research collaboration with Dr. Scott Friedman, Director Liver

Diseases, Mt. Sinai School of Medicine & President, American

Association for the Study of Liver Diseases

•

PRO-GR

300,

a

first

in

class,

carbohydrate

compound

has

shown

in

pre-clinical

models

to

not

only

arrest

disease

progression

but

also

to

reverse

disease

progression

23

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Reduces

the

production

of

Collagen

Collagen

is

central

to

fibrogenesis

diseases

and

the

scarring

of

organs.

Reduces Expression of Matrix

Metalloproteinase -2 (MMP-2)

MMP-2 has been correlated to the

severity

of

fibrosis

in

hepatitis

C.

Reduces Expression of TGFBR1

TGFBR1 plays a key role in initiating the

cascade of events  causes the formation

of

fibrosis

/

scar

tissue

Mechanism of Action -

Mechanism of Action -

Effect

Effect

on Fibrotic Markers In-vitro

on Fibrotic Markers In-vitro

Addition of PRO-GR 300 to fibrotic liver cells:

24

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Reversal of Fibrosis with

PRO–GR 300 after 4 weeks

of treatment

Liver Fibrosis, induced by injection

of chemical toxin for 8 weeks

Rat

Fibrosis

Model

Proof of Concept

Proof of Concept

25

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Other Fibrosis Applications

•

The same receptors influence many types of Fibrosis

•

Therefore PRO-GR 300 may be effective in different types of

Fibrosis

•

Chemical toxicity, microbial infection & physical injury cause

hepatic, renal, cardiac and pulmonary fibrosis

•

Kidney Fibrosis

–

12 million people suffer from kidney fibrosis in the U.S.

–

Research collaboration with Brigham and Women's

Hospital -

affiliate of Harvard Medical School

26

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Regulatory Strategy

27

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Regulatory Strategy

•

Submit final report for completed Phase II end stage patient trial

•

Continue Phase II trials underway

•

Drug Master File (Mfg data) to FDA

•

Initiate IND for non-intravenous indications, e.g., Melanoma

•

File for Approval to Market DAVANAT®

as Excipient with 5-FU

•

Animal studies needed to add DAVANAT®

to other chemos

•

Regional partnership approach for DAVANAT®

•

Partner for Phase III trials

Oncology

Fibrosis

•

Animal studies needed to extend proof of concept

•

Accelerate liver & kidney pre-clinical trials

•

File IND for human trials

•

Seek partnership

28

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Product Development Pipeline Jan 2008

PRODUCT

INDICATION

DISCOVERY

PRE-CLINICAL

PHASE 1

PHASE 2

DAVANAT

®

/ 5-FU line I

DAVANAT

®

/ 5-FU/LV/

AVASTIN

®

line I

DAVANAT

®

/ 5-FU line IV

PRO-GR 300

Biliary Cancer

Ongoing

Colorectal  Cancer

Ongoing

All Solid Tumors

Completed

Liver Disease

Microbial Disease

PHASE 3

DAVANAT

®

/ 5-FU line IV

Colorectal Cancer

Completed

PRO-NAC 050

29

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

2008 Milestones

•

Submit Drug Master File (DMF) -

First Quarter

•

File Investigative New Drug (IND) Application: Triggers

FDA Review of DMF -

Second Quarter

•

DMF approval projected –

Second/Third Quarter

•

License DAVANAT®

in regions outside U.S. –

Third Quarter

•

Submit data needed for approval as excipient to 5-FU –

Fourth Quarter

•

Continue to complete research agreements

•

Actively pursue corporate partnerships

30

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Business Opportunities 

Several

Multi-billion dollar markets can

be addressed

31

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Business Opportunities

•

Oncology

–

Excipient to 5-FU, improve results & reduce side effects

–

Eliminates/reduces need for additional drugs to treat side effects

–

Extend patent life of chemo drugs

–

Only animal studies needed to combine with other chemo

–

New indications -

melanoma

–

Regional licenses

–

Partner with big Pharma to fund trials

•

Avastin®

sales in 2007 $2.9 billion –

Works with 5-FU

–

Low Cost to Produce

32

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Business Opportunities           

Several Multi-billion dollar markets can be

addressed

•

Fibrosis

–

Accelerate pre-clinical trials based on proven safety of

carbohydrates and DAVANAT®

•

Liver

•

Kidney

–

File IND

–

Start clinical trials ASAP

–

Early partnerships

–

New indications –

lung fibrosis

33

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

CORPORATE

34

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Corporate Summary

•

PRW began operations in 2001

•

Five U.S. patents issued

•

Capital raised: $39.5 million (cumulative)

•

Shares outstanding: 40.4 million (11/01/07)

•

Fully diluted: 52.1 million (11/01/07)

•

Completed Phase l/ll cancer trials, line 3-4

•

Two ongoing Phase ll trials, line 1, biliary & colorectal cancer

•

PRO-GR 300

in pre-clinical trials to treat fibrosis

•

Plan to commercialize technology and products through

corporate partnerships

•

Carbohydrate technology platform enables:

–

New intellectual property

–

Product line extensions

–

Safer and more effective drugs

35

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Management Team

•

David Platt, Ph.D., Chairman & Chief Executive Officer

–

Co-founder, co-developer of Glycoscience technology. Founder: SafeScience; developed

anti-angiogenesis drug.  U of Michigan, Weizmann Institute, Hebrew U

•

Theodore Zucconi, Ph.D., President

–

35 + years experience in operations management, R&D, problem solving, product

development and strategic planning

•

Anatole Klyosov, Ph.D., D.Sc., Chief Scientist

–

Co-founder, co-developer of Glycoscience technology. National Prize in Science &

Technology (Russia); Visiting Biochemistry Prof at Harvard.  Moscow State U

•

Eliezer Zomer, Ph.D., Exec. V.P., Clinical Development & Mfg

–

Former Research Associate at Harvard Medical

•

David Donabedian, Ph.D., MBA, Business Development (Consultant)

–

12 years in life sciences;  VP, Bus Dev, Surface Logix; Accenture;  Dow Chemical

•

Anthony Squeglia, MBA, Chief Financial Officer

–

25 years in finance, strategic planning, marketing & investor relations

•

Maureen Foley, Chief Operating Officer

–

25 years in biotech, high-tech in operations management

•

Bruce Silver, M.D., Medical Director (Consultant)

–

20 + years in oncology; CRO

36

P R O  

-

P H A R M A C E U T I C A L S ,  I N C.

A D V A N C I N G   D R U G S   T H R O U G H   G L Y C O S C I E N C E

®

Amex: P R W

Summary

•

Proprietary Technology With Multiple Current and

Future Applications

•

Excipient

for Existing Chemotherapy Protocols

•

Reduces or Eliminates Adverse Side Effects and

Lowers Cost of Treatment

•

Proven Effective in Targeting Lectin Receptors

Specific to Cancer Cells

•

New Compound (drug) has Shown Ability to

Reverse Liver Fibrosis

•

Oncology and Fibrosis –

Multi Billion Dollar Markets

37